Erratum to "Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice" [Vaccine 2007; 25 (45): 7743-53] (DOI:10.1016/j.vaccine.2007.09.023);Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice

Vaccine

Volumn 25, Issue 45, 2007, Pages 7743-7753

  Sharon, Melamed ^a   Nir, Paran ^a   Lior, Katz ^a   David, Ben Nathan ^a   Tomer, Israely ^a   Paula, Schneider ^a   Reuven, Levin ^a   Shlomo, Lustig ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Murine challenge model; Scarification; Smallpox vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; SMALLPOX VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DRUG POTENCY; ERADICATION THERAPY; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALLPOX; VACCINATION; VACCINIA VIRUS; VIRUS STRAIN; VIRUS VIRULENCE; WORLD HEALTH ORGANIZATION;

EID: 35348871886     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.077     Document Type: Erratum

References (40)

1. Fenner F., Henderson D., Arita I., Jezek Z., and Ladnyi I. Smallpox and its eradication (1988), World Health Organization, Geneva
2. Lane H.C., Montagne J.L., and Fauci A.S. Bioterrorism: a clear and present danger. Nat Med 7 12 (2001) 1271-1273
3. Orr N., Forman M., Marcus H., Lustig S., Paran N., Grotto I., et al. Clinical and immune responses after revaccination of Israeli adults with the Lister strain of Vaccinia virus. J Infect Dis 190 7 (2004) 1295-1302
4. Putz M.M., Midgley C.M., Law M., and Smith G.L. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12 11 (2006) 1310-1315
5. Empig C., Kenner J.R., Perret-Gentil M., Youree B.E., Bell E., Chen A., et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 24 17 (2006) 3686-3694
6. Schriewer J., Buller R.M., and Owens G. Mouse models for studying orthopoxvirus respiratory infections. Meth Mol Biol 269 (2004) 289-308
7. Jordan R., and Hruby D. Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev Anti Infect Ther 4 2 (2006) 277-289
8. Tscharke D.C., and Smith G.L. A model for Vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80 Pt 10 (1999) 2751-2755
9. Eyal O., Olshevsky U., Lustig S., Paran N., Halevy M., Schneider P., et al. Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera. J Virol Meth 130 1-2 (2005) 15-21
10. Majer M., and Plotkin S.A. Strains of Human Viruses (1972), S. Karger, Basel
11. Gerichter C. Preparation of vaccine against smallpox in chorioalantois membranes of chicken embryos. Public Health (Israeli Ministry of Health, Jerusalem) 9 (1966) 36-41
12. Staib C., Suezer Y., Kisling S., Kalinke U., and Sutter G. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J Gen Virol 87 Pt 10 (2006) 2917-2921
13. Hahn C.S., Hahn Y.S., Braciale T.J., and Rice C.M. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc Natl Acad Sci USA 89 7 (1992) 2679-2683
14. Finney D. Statistical Methods in Biological Assays (1952), Charles Griffin & Company Limited, London
15. Chakrabarti S., Sisler J.R., and Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23 6 (1997) 1094-1097
16. Fogg C., Lustig S., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 78 19 (2004) 10230-10237
17. Lustig S., Fogg C., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 79 21 (2005) 13454-13462
18. Reed L., and Muench H. A simple method of estimating fifty percent end points. Am J Hyg 27 (1938) 493-497
19. Henderson D.A. The looming threat of bioterrorism. Science 283 5406 (1999) 1279-1282
20. Hutin Y.J., Williams R.J., Malfait P., Pebody R., Loparev V.N., Ropp S.L., et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996-1997. Emerg Infect Dis 7 3 (2001) 434-438
21. Nalca A., Rimoin A.W., Bavari S., and Whitehouse C.A. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 41 12 (2005) 1765-1771
22. Stephenson J. Monkeypox outbreak a reminder of emerging infections vulnerabilities. JAMA 290 1 (2003) 23-24
23. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100 16 (2003) 9458-9463
24. Phelps A., Gates A.J., Hillier M., Eastaugh L., and Ulaeto D.O. Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model. Vaccine 23 27 (2005) 3500-3507
25. Phelps A.L., Gates A.J., Hillier M., Eastaugh L., and Ulaeto D.O. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine 25 1 (2007) 34-42
26. Abdalrhman I., Gurt I., and Katz E. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA). Vaccine 24 19 (2006) 4152-4160
27. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., and Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341 1 (2005) 91-101
28. Kenner J., Cameron F., Empig C., Jobes D.V., and Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 24 47-48 (2006) 7009-7022
29. Saijo M., Ami Y., Suzaki Y., Nagata N., Iwata N., Hasegawa H., et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol 80 11 (2006) 5179-5188
30. Fulginiti V.A. Smallpox vaccination: a review of adverse events for contemporary health care providers. In: Scheld W.M., Hooper D.C., and Hughes J.M. (Eds). Emerging infections 7 (2007), ASM Press, Washington, DC 343-365
31. Frey S.E., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K., et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346 17 (2002) 1265-1274
32. el-Ad B., Roth Y., Winder A., Tochner Z., Lublin-Tennenbaum T., Katz E., et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 161 3 (1990) 446-448
33. Viner K.M., and Isaacs S.N. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect 7 4 (2005) 579-583
34. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 9 9 (2003) 1131-1137
35. Puissant B., and Combadiere B. Keeping the memory of smallpox virus. Cell Mol Life Sci 63 19-20 (2006) 2249-2259
36. Stienlauf S., Shoresh M., Solomon A., Lublin-Tennenbaum T., Atsmon Y., Meirovich Y., et al. Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 17 3 (1999) 201-204
37. Dasgupta A., Hammarlund E., Slifka M.K., and Fruh K. Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class I molecules. J Immunol 178 3 (2007) 1654-1661
38. Lee M.S., Roos J.M., McGuigan L.C., Smith K.A., Cormier N., Cohen L.K., et al. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J Virol 66 5 (1992) 2617-2630
39. Meseda C.A., Garcia A.D., Kumar A., Mayer A.E., Manischewitz J., King L.R., et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339 2 (2005) 164-175
40. Andrew M.E., Coupar B.E., and Boyle D.B. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immunol Cell Biol 67 Pt 5 (1989) 331-337